Zyden enters royalty agreement with Changshu Wanxing Chemical

By Elaine Rigoli

Tampa, Fla., July 24 - Zyden Gentec Ltd. said Monday that it has successfully completed the technology transfer for the synthesis of iminostilbenes, an intermediate widely used in different antidepressants, to Changshu Wanxing Chemical Co., Ltd. of China.

Under the agreement, Changshu will pay Zyden a royalty of 2% on the gross sales of the product, which should total between $8 million to $10 million in annual sales.

Zyden said it has also successfully developed technology for the synthesis of the antiviral drug Tamiflu and is now looking for partners to market the drug internationally.

Zyden is a pharmaceutical company located in Rajasthan, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.